MAZE
Maze Therapeutics, Inc.Company with tickers: MAZE
CIK
1842295
CUSIP
578784100
Shares Outstanding
55,345,261
Price History
Institutional Holders
Short Volume
Short Interest
Fails to Deliver
Financials
SEC Filings
Earnings Calls
Insider Trades
Congressional Trades
| Line Item | Value | Unit | Period End | Form | Filed |
|---|---|---|---|---|---|
| Revenue | — | ||||
| Revenue (ASC 606) | $20,000,000 | USD | 2026-03-31 | 10-Q | 2026-05-12 |
| Cost of Revenue | — | ||||
| Gross Profit | — | ||||
| Operating Expenses | $35,401,000 | USD | 2025-03-31 | 10-Q | 2026-05-12 |
| Research & Development | $27,580,000 | USD | 2025-03-31 | 10-Q | 2026-05-12 |
| Operating Income | $-35,401,000 | USD | 2025-03-31 | 10-Q | 2026-05-12 |
| Net Income | $-32,786,000 | USD | 2025-03-31 | 10-Q | 2026-05-12 |
| EPS (Basic) | $-1.15 | USD/shares | 2025-03-31 | 10-Q | 2026-05-12 |
| EPS (Diluted) | $-1.15 | USD/shares | 2025-03-31 | 10-Q | 2026-05-12 |